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Duc Si Dong, PhD,|| Stephen F. Konieczny, PhD,§ and Pamela Itkin-Ansari, PhD*‡Objectives: Pancreatic ductal adenocarcinoma (PDA) initiates from
quiescent acinar cells that attain a Krasmutation, lose signaling from basic
helix-loop-helix (bHLH) transcription factors, undergo acinar-ductal meta-
plasia, and rapidly acquire increased growth potential. We queried whether
PDA cells can be reprogrammed to revert to their original quiescent acinar
cell state by shifting key transcription programs.
Methods: Human PDA cell lines were engineered to express an inducible
form of the bHLH protein E47. Gene expression, growth, and functional
studies were investigated using microarray, quantitative polymerase chain re-
action, immunoblots, immunohistochemistry, small interfering RNA, chro-
matin immunoprecipitation analyses, and cell transplantation into mice.
Results: In human PDA cells, E47 activity triggers stable G0/G1 arrest,
which requires the cyclin-dependent kinase inhibitor p21 and the stress
response protein TP53INP1. Concurrently, E47 induces high level
expression of acinar digestive enzymes and feed forward activation of
the acinar maturation network regulated by the bHLH factor MIST1.
Moreover, induction of E47 in human PDA cells in vitro is sufficient
to inhibit tumorigenesis.
Conclusions: Human PDA cells retain a high degree of plasticity, which
can be exploited to induce a quiescent acinar cell state with reduced tumor-
igenic potential. Moreover, bHLH activity is a critical node coordinately
regulating human PDA cell growth versus cell fate.
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P ancreatic ductal adenocarcinoma (PDA) arises from theexocrine pancreas, which is composed of 2 major cell
populations—acinar cells that produce digestive enzymes and
duct cells that are tasked with transporting acinar enzymes to
the duodenum. Despite the ductal morphology of PDA, lineage
tracing studies have revealed that the tumors arise from the acinar
compartment.1–9 In response to oncogenic Kras, quiescent acinar
cells enter the cell cycle and undergo acinar-ductal metaplasia
(ADM) where the cells silence acinar transcription programs.
The cells acquire a duct-like transcriptome that drives the forma-
tion of precancerous pancreatic intraepithelial neoplasia (PanIN)
lesions.5,6,9 Subsequent mutations in additional oncogenes or
tumor-suppressor genes fuel disease progression, leading to ag-
gressive PDA. Whether this process is reversible is not known,
but if tumor cells could be induced to enter a quiescent, differen-
tiated acinar cell state, this would provide an important new
strategy for combating this deadly disease.
During ADM, tumor-initiating cells repress expression of
the acinar transcription factors MIST1 and pancreas-specific
transcription factor 1a (PTF1a).7,8,10–14 leading to loss of acinar
cell polarity, gap junction complexes, and key acinar gene prod-
ucts, including digestive enzymes. Because PTF1a and MIST1
belong to the basic helix-loop-helix (bHLH) family of transcrip-
tion factors, they must form bHLH dimer complexes to bind
to cognate E-box DNA sites found in target genes.15 The bHLH
family members assemble as either homodimer or heterodi-
mer complexes with other bHLH proteins such as E47.16–21 The
bHLH family is also subject to negative regulation by the inhibi-
tor of DNA binding (ID) family of proteins (ID 1–4 in humans).
IDs contain an α-helical HLH dimerization motif but lack a basic
domain, resulting in dominant-negative bHLH/ID heterodimers.15
We and others have shown that ID3 protein levels are greatly
elevated in PDA tumors.18–20Moreover, we showed that upregula-
tion of ID3 is sufficient to induce cell cycle entry in quiescent
human exocrine tissue.18 High ID3, as well as attenuated expres-
sion of bHLH proteins, suggests that bHLH transcriptional
networks are profoundly dysregulated in PDA and that restoring
normally high bHLH activity might promote pancreatic cellu-
lar homeostasis. The misregulation of bHLH and HLH factors
in PDA provides a testable model to determine whether shifting
these regulatory networks would revert cells towards their original
acinar cell state. To this end,wegeneratedPDA lines expressing an
inducible form of E47. E47 was chosen because of its versatil-
ity in binding to client bHLH proteins, its known regulation of
acinar gene expression in concert with PTF1a,20 and its activity
as a homodimer. Moreover, E47 efficiently binds and thus se-
questers ID3.18,22 Initially, we found that induced E47 activity
in PANC-1 cells led to reduced Ki67 expression.18 Here, we reportPancreas • Volume 44, Number 5, July 2015
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and that, mechanistically, this requires upregulation of p21CIP1/
WAF1 and the stress response protein TP53INP1. Remarkably, cell
cycle exit is accompanied by reactivation of the acinar cell differ-
entiation program, including robust expression of acinar digestive
enzyme genes. In addition, E47-induced cells re-express Mist1, a
key bHLH transcription factor that controls the acinar maturation
program.14,23,24Moreover, we show thatMIST1 is required for the
re-establishment of acinar gap junctions. Importantly, induction of
E47 in vitro was sufficient to inhibit PDA cell tumorigenesis, be-
cause E47-expressing cells maintained growth arrest and acinar
gene expression following transplantation. The data suggest that
changes to the acinar cell transcriptome can have a dominant role
in PDA pathogenesis. Collectively, the results demonstrate that
PDA cells maintain a previously unrecognized level of cellular
plasticity that is amenable to restoring a quiescent acinar cell state.
We propose that bHLH transcriptional activity serves as the
fulcrum dictating the growth and differentiation status of acinar
cells undergoing oncogenic insults, findings which should sup-
port novel avenues for therapeutic intervention.MATERIALS AND METHODS
Cell Culture
Human pancreatic adenocarcinoma cell lines from the ATCC
(Rockville, Md), PANC-1 (CRL-1469),25 BxPC-3 (CRL-1687),26
and MiaPaCa2 (CRL-1420)27 were cultured in Roswell Park Me-
morial Institute medium 1640 or Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum in 5% CO2
at 37°C. E47-inducible cell lines were generated by infection with
a retroviral vector expressing E47 fused to a tamoxifen-inducible
modified estrogen receptor (MER). This vector also expresses
CD25, which was used to isolate stable lines by fluorescence-
activated cell sorting (FACS) as previously described.18,19 E47
activity was induced by incubating cells with tamoxifen for 48 to
96 hours unless otherwise noted.
Transfections
For flow cytometry, parental PDA cell lines were transfected
(Lipofectamine 2000; Invitrogen) with green fluorescent protein
or inducible E47 plasmids and incubated with tamoxifen for 48
to 72 hours. For knockdown studies, PDA cells were transfected
with small interfering RNA (siRNA) to p21CIP1/WAF1 (AM51331;
Applied Biosystems and J-003471–12; Dharmacon), TP53INP1
(J-016159–05–0005, J-016159–05; Dharmacon), Id3 (J-009905–07,
J-009905–08; Dharmacon), or Mist1 (J-009045–15, J-009045–16;
Dharmacon) using Lipofectamine RNAiMAX (Invitrogen) and
incubated for 96 hours. For each gene, at least 2 independent
siRNAs were employed.
Flow Cytometry
Live sorting: cells were immunostained with fluorescein
isothiocyanate-conjugated mouse antihuman CD25 (1:100, BD
Biosciences) as previously described.18 Cell cycle analysis: cells
were fixed with 100% ethanol, incubated with antihuman CD25
and propidium iodide (Invitrogen) for analysis on a FACS Canto
cytometer (BD Biosciences). G0/G1, S, and G2/M phase estimates
were generated by modeling data with ModFitLT software (Verity
Software House).
Microarray Analysis
Four biological replicates of PANC-1/E47 cells were harvested
from each of the following 3 treatment groups: untreated controls© 2015 Wolters Kluwer Health, Inc. All rights reserved.and 2 different doses of tamoxifen for 48 hours. Data are deposited in
gene expression omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo),
accession number GSE55999. Briefly, RNA was labeled with
biotin-16-UTP and hybridized to HumanHT-12 v4 Expression
BeadChip (Illumina, Inc). BeadChips were scanned and normal-
ized with a BeadArray Reader. The resulting data were collected
by Scanner software and preprocessed by GenomeStudio soft-
ware (Illumina, Inc). Principal component analysis of differen-
tial gene detection was performed with Partek Genomics Suite
(Partek, Inc). Hierarchical clustering and other statistical anal-
yses were performed using R/Bioconductor software package
(www.bioconductor.org). A change in gene expression of at least
1.5-fold at the 99% confidence level was considered signifi-
cant. Pathway analyses were performed with Ingenuity Pathway
Analysis software (Ingenuity Systems, Inc). GSE16515 and
GSE15471 datasets were used to identify genes, which are highly
expressed in human PDA tumors relative to normal pancreas tis-
sue, and to determine the correlation between Id3 and TP53INP1
expression in PDA-tumor samples relative to control tissue (statis-
tically analyzed by Pearson coefficient).28,29 Gene Set Enrichment
Analysis (GSEA) was used to compare the E47-induced gene set
versus GSE1133 and GSE2361 gene sets comparing normal hu-
man pancreas with other tissues30,31 using the NCBIGEO2R tool.
The final pancreas-enriched gene sets were further defined by
the following criteria: (1) greater than 2.0-fold change in expres-
sion, compared with other tissues; (2) P < 0.05; (3) greater than
50 expression signals (“Present”) from detection calls in pancreas
samples; and (4) absent genes in the islet-enriched gene set.Immunostaining
Cultured cells were fixed in 4% paraformaldehyde (USB
Corp), permeabilized with 0.3% Triton X-100, and incubated
with the following primary antibodies: mouse anti-E47 (1:100,
554077; BD Pharmingen), mouse anti-Ki67 (1:100, 550609; BD
Biosciences), rabbit anti-p21CIP1/WAF1 (1:100, ab7960; Abcam),
rabbit anti-ZO.1 (1:100, 402200; Invitrogen), mouse anti-PRSS2
(1:100, SAB140022; Sigma), rabbit anti-CX32 (1:100, ab66613;
Abcam), mouse anti-MIST1 (in-house affinity purified, 1:50),
and mouse antiactin (1:100, ab8224; Abcam). Secondary antibod-
ies were conjugated to donkey antirabbit Alexa Fluor 488 (1:400,
A21206; Invitrogen) or donkey antimouse rhodamine (1:400,
100185–414; Jackson ImmunoResearch). Nuclei were counter-
stained with DAPI (4′,6-diamidino-2-phenylindole dihydrochloride;
AppliChem). Digital images were acquired with fluorescence or con-
focal microscopes equipped with a digital camera (Nikon). Paraf-
fin sections (5 μm) of explanted tumors were subjected to antigen
retrieval (Dako: pH, 6.0). Endogenous peroxidase was blocked
with 3% hydrogen peroxide (H2O2) and methanol followed by
nonspecific blocking with BlockM (BioCare) for 25 minutes, pri-
mary antibody at 4°C, and MM-HRP-Polymer (Biocare) at room
temperature. The color reaction was developed using DAB (3,3′-
diaminobenzidine tetrahydrochoride) (Sigma-Aldrich), counter-
stained with Mayer's hematoxylin (Sigma-Aldrich), and mounted
in Cytoseal 60 (Thermo Scientific).Real-Time qPCR Analysis
Ribonucleic acid was extracted with an RNeasy Mini Kit
(Qiagen) and reverse transcribed with qScript cDNA Supermix
(Quanta). Real-time qPCR was performed using the LightCycler 480
II system with SYBR Green I (Roche), and gene expression was nor-
malized to 18S rRNA. Primer sequences are provided in Table S1,
Supplemental Digital Content, http://links.lww.com/MPA/A363.www.pancreasjournal.com 719
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PANC-1/E47 cell lysates were blotted with antibodies to
p21CIP1/WAF1, Ki67 (Leica Biosystems),α/βHSP90 (Santa Cruz),
MIST1 (in-house affinity purified), as well as those listed in im-
munofluorescence studies, resolved on 4% to 12% SDS-PAGE
gels (Thermo Scientific), and transferred to nitrocellulose mem-
branes (LI-COR Biosciences). Membranes were incubated with
infrared dye-conjugated secondary antibodies (LI-COR) and im-
aged with a LI-COR Odyssey v 3.0 imaging system.
Immunoprecipitation
The PANC-1 cells were transfected with Id3-Flag plasmids
using Reagent (Invitrogen). After 6 hours of incubation at
37 °C, growth media were changed. Tamoxifen was added to
concentration of 4 μm. After incubation with tamoxifen for
48 hours, cells were harvested using cell lysis buffer (TrisHCl,
20 mM [pH, 7.5]; Triton X-100, 1%; glycerol, 10%; NaCl,
300 mM; EDTA, 0.5 mM [pH8.0]; Na3VO4, 1 mM; protease in-
hibitors] for immunoprecipitation. The FLAG fusion proteins
were extracted using Anti-FLAG M2 Magnetic Beads, proteins
were electrophoretically separated on SDS-4–12% polyacryl-
amide gels (Thermo Scientific), transferred onto nitrocellulose
membranes (LI-COR Biosciences), blocked with Odyssey
Blocking Buffer (LI-COR Biosciences), and incubated at
RT with anti-FLAG (Abcam) and anti-β-actin (Abcam) as
control. Secondary antibody detection was performed with
infrared dye conjugates (LI-COR Biosciences).
Chromatin Immunoprecipitation
The PANC-1/E47 cells were induced with 1-μm tamoxifen
or EtOH at 70% confluence. After 48-hour tamoxifen treatment,
the cells were fixed in a 1% formaldehyde-phosphate-buffered sa-
line solution. Formaldehyde was neutralized using glycine. The
cells were lysed, and DNA was fragmented via sonication using
15-second pulses 5 times per sample. Thirty micrograms of chro-
matin was incubated with 4 μg of either anti-transcription factor
E2-Alpha or anti-immunoglobulin G. Chromatin was extracted
using Sepharose A beads, and crosslinks were reversed using
NaCl. Deoxyribonucleic acid was extracted and purified
using Proteinase K digestion and the QIAquick PCR purifica-
tion kit. Chromatin immunoprecipitation (ChIP) amplicon primer
sequences are provided in Table S2, Supplemental Digital Content,
http://links.lww.com/MPA/A363.
Animal Studies
Forty-eight Severe Combined Immunodeficiency (SCID)/beige
mice were purchased from The Jackson Laboratory. This study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of LaboratoryAnimals of the National
Institutes of Health. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Sanford-Burnham
Medical Research Institute, institutional animal welfare assurance
number A3053–01. All surgery was performed under isoflurane
anesthesia, and all efforts were made to minimize suffering. The
PANC-1/E47 cells or parental PANC-1 cells were treated with ta-
moxifen for 8 days in vitro before transplantation. The BxPC-3/
E47 cells were untreated or treated with tamoxifen for 48 hours
in vitro before transplantation. Three million live cells (cells ex-
cluding Trypan Blue) were injected into the flank of SCID/beige
mice. The condition of the mice was examined daily. On a weekly
basis, the animals were weighed and imaged by ultrasound to
measure tumor volumes. The formula used to calculate tumor vol-
ume is 4/3 3.14 average radius of length average radius of720 www.pancreasjournal.comwidth  average radius of depth. The animals were humanely
killed when they showed clinical signs of distress or pain; these in-
cluded hunched posture, ruffled coat, open sores, slow breathing,
or reduced response to external stimuli. The micewere euthanized
by CO2 asphyxiation. All aspects of the animal protocol were ap-
proved by Institutional Animal Care and Use Committee.
Statistical Analyses
Data are expressed as mean (SD) or standard error of the
mean (SEM). Groups were compared using Student t test. Pearson
coefficient was used when indicated.
RESULTS
Induction of E47 Causes Stable G0/G1 Arrest in
Human PDA Cells
In an effort to increase bHLH activity in aggressively grow-
ing human PDA cells, we stably transduced 3 human PDA lines
with a tamoxifen-inducible form of E47 fused to a MER, gen-
erating the PDA/E47 lines PANC-1/E47, BxPC-3/E47, and
MiaPaCa2/E47.18,19,32 All PDA/E47 cell lines express high
levels of E47, and nuclear localization of E47 is induced by
tamoxifen treatment (Fig. S1A, Supplemental Digital Content,
http://links.lww.com/MPA/A363). Because the rationale for in-
creasing E47 expression was in part to sequester ID3 in PDA
cells, we next investigated whether E47MER bound to ID3 in
PDA/E47 cells. Using immunoprecipitation and western blots,
we show that both endogenous E47 and ectopic E47MER form
protein complexes with ID3 (Fig. S1B, Supplemental Digital
Content, http://links.lww.com/MPA/A363).
Recently, we showed that upon induction of E47 in PANC-1
cells, Ki67 expression was diminished.18 Here, we queried
whether this response was universal among different PDA cell
lines. As shown in Figure 1A, induction of E47 activity produced
rapid loss of Ki67 expression in all cell lines. Importantly, tamox-
ifen treatment of parental PDA cells lacking ectopic E47 had no
effect on Ki67 expression, indicating that cell cycle exit was due
to induced E47 activity, not to tamoxifen (Fig. S2, Supplemental
Digital Content, http://links.lww.com/MPA/A363). Remarkably,
for an 8-day culture period, the number of tamoxifen-induced
PANC-1/E47 cells remained static or declined, compared with
uninduced PANC-1/E47 cells that expanded 68-fold (Fig. 1B).
To determine whether E47 arrested PDA cells in G0/G1, S, or
G2/M, flow cytometry was employed to assess DNA content, re-
vealing that E47 induced primarily G0/G1 arrest (Fig. 1C). The
observed G0/G1 arrest suggested that E47 might generate stable
changes in the cell cycle. To test this hypothesis, E47 was induced
with tamoxifen for 8 days, followed by culture for an additional
8 days in the absence of tamoxifen. Notably, tamoxifen-treated
cells maintained a nonproliferative state even when switched to
normal growth medium (Fig. S3, Supplemental Digital Content,
http://links.lww.com/MPA/A363), revealing that temporary in-
duction of E47 activity was sufficient to arrest cells for prolonged
periods.
E47 Induces Global Gene Expression Changes
Associated With Cell Cycle, Cancer, and
Tissue Differentiation
To systematically probe the alterations in gene expression
promoted by E47, we performed microarray analyses of PANC-
1/E47 cells with and without tamoxifen treatment (GSE55999).
Principal component analysis of microarray data, which measures
variance between the sample sets, revealed that E47 induced highly© 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. E47 induces G0/G1 arrest and significantly downregulates cancer-associated genes in PDA cells. A, Immunostaining for the replication
marker Ki67 (red) and DAPI (blue), 200. B, Growth curves (log scale) for PANC-1/E47 cells. *P < 0.05, ***P < 0.001, n = 3 per group.
C, Percentage of cells in individual cell cycle phases determined by flow cytometry. D, Venn diagramdepicts genes upregulated in human PDA
tumors relative to adjacent tissue (GSE16515, red) versus genes downregulated by E47 activity in PANC-1/E47 cells (dataset deposited-
GSE55999, blue), overlap P = 1.1E−40. E, Heat map frommicroarray data showing 50 genes most profoundly downregulated by E47 activity,
n = 4 biological replicates each. Arrows depict examples of genes validated by quantitative polymerase chain reaction (qPCR) in 3 PDA/E47
cell lines (Fig. S4, Supplemental Digital Content, http://links.lww.com/MPA/A363). (Note: for simplicity, E47ER cells treated with or without
tamoxifen are labeled with the name of the parental cell line +/− E47 activity).
Pancreas • Volume 44, Number 5, July 2015 Reprogramming Pancreatic Cancer Cellssignificant changes in gene expression in PDA cells (Fig. S4A,
Supplemental Digital Content, http://links.lww.com/MPA/A363).
Unbiased bioinformatics analysis identified gene sets cluster-
ing within key biological themes of “Cell Cycle,” “Cancer,”
and “Tissue Development” (Fig. S4B, Supplemental Digital
Content, http://links.lww.com/MPA/A363). Interestingly, when
the microarray data were compared with datasets from PDA
tumors, we found that 47% of the genes downregulated in
the E47 groups were those commonly upregulated in PDA (P =
1 10−40), suggesting that E47 activity promotes a return towards
tissue homeostasis (Fig. 1D, E, S4C, Supplemental Digital Con-
tent, http://links.lww.com/MPA/A363). Among the genes, most
profoundly inhibited by E47 were the PDA-associated cell cycle
activators topoisomerase2A (Top2A), aurora kinase A (AURKA),
and Cyclin B2 (CCNB2) (Fig. 1E). Importantly, PCR analysis
of these genes confirmed that they were significantly down-
regulated by E47 in all cell lines tested (Fig. S5, Supplemental
Digital Content, http://links.lww.com/MPA/A363), revealing uni-
versally conserved effects of E47 in PDA cells.
E47 Dependent Growth Arrest Requires Induction
of p21 and TP53INP1 Expression
To probe the mechanism by which E47 activity mediates cell
cycle arrest, we considered that E47 might induce expression of
cell cycle inhibitors, which often exhibit pleiotropic effects. In-
deed, one of the genes highly upregulated by E47 in the microar-
ray profile was the cyclin-dependent kinase inhibitor (CDKI)
CDKN1ACIP1/WAF1/Kip1 (p21) (Fig. S4B, Supplemental Digital
Content, http://links.lww.com/MPA/A363). The p21 was of par-
ticular interest because its expression is greatly diminished in
PDA and enforced expression halts PDA cell growth.33 Validation
by Real-Time qPCR confirmed that E47-induced robust increases
in p21 mRNA in all cell lines tested. Moreover, p21 was also© 2015 Wolters Kluwer Health, Inc. All rights reserved.induced at the protein level (Figs. 2A, S6, Supplemental Digital
Content, http://links.lww.com/MPA/A363). To determine whether
p21 is essential for E47-mediated growth arrest, we performed
siRNA-mediated knockdown, achieving a 90% reduction in p21
mRNA, aswell as reduced protein levels (Figs. S7A, B, Supplemen-
tal Digital Content, http://links.lww.com/MPA/A363). Inhibition of
p21 led to a significant increase in the number of Ki67-expressing
PDA cells (9.1%–28.6%) (Figs. 2B, C), supporting a required role
for p21 in E47-mediated cell cycle arrest. Chromatin immunopre-
cipitation studies further established that E47 binds directly to the
CDKN1A promoter and that binding is greatly elevated in tamoxifen-
treated cells (Fig. 2D). Interestingly, microarray and PCR analyses
also showed that E47 induced high level expression of an additional
member of the Cip/Kip CDKI family, CDKN1C (p57Kip2) in PDA
cells. However, reduction of p57Kip2 in PDA cells, using our previ-
ously validated short hairpin RNA,32 revealed that p57Kip2 did not
attenuate E47-mediated arrest. Thus, the function of the Cip/Kip
CDKI family members in PDA is highly context specific.
Because reversal of E47-mediated growth arrest by p21
knockdown was not complete, we searched for additional effec-
tors of cell cycle exit. Microarray (Fig. S4B, Supplemental Dig-
ital Content, http://links.lww.com/MPA/A363) and confirmatory
qRT-PCR studies revealed that E47 activity also markedly induced
expression of the stress response protein TP53INP1 (tumor protein
p53 inducible nuclear protein 1) in all PDA lines tested (Fig. 2E).
Interestingly, like p21, TP53INP1 expression is diminished in
PDA and its forced expression inhibits PDA cell growth.34 Re-
markably, loss of TP53INP1 by siRNA knockdown completely re-
versed E47-mediated growth arrest in PDA cells (Figs. 2E, S7C,
Supplemental Digital Content, http://links.lww.com/MPA/A363),
revealing for the first time that TP53INP1 is an essential component
of an E47-induced transcriptional network. The finding that bHLH
activity and TP53INP1 expression are linked in the same pathway
in PDA cells led us to predict that tumors expressing the highestwww.pancreasjournal.com 721
FIGURE 2. E47-induced cell cycle arrest requires p21 and TP53INP1. A, RT-qPCR analysis of p21mRNA levels in PDA/E47 cells and
immunoblot of p21 protein levels in PANC-1/E47 cells. B, Percentage of Ki67+ cells after treatment with control (Con) or p21-specific siRNA.
C, Immunostaining for Ki67 (red) andDAPI (blue) in PANC-1/E47 cells, untransfected (−) or transfectedwith control siRNA (CON), p21-specific
siRNA, or TP53INP1-specific siRNA, 200. D, ChIP assays confirm that E47 accumulates at the CDKN1a promoter in Panc-1/E47 cells
induced with tamoxifen. E, RT-qPCR analysis of TP53INP1 expression in PDA/E47 cells and percentage of Ki67+ cells after TP53INP1
knockdown. F, Correlation between Id3 and TP53INP1 expression in individual human PDA tumors using published GEO datasets.25,26
Note: negative values on axes denote lower expression in tumors relative to normal pancreas tissue. The negative R value denotes an inverse
relationship between Id3 (high) and TP53INP1 (low) expression. A-E, Results are representative of at least 3 independent experiments.
Kim et al Pancreas • Volume 44, Number 5, July 2015levels of the bHLH inhibitor ID3 would exhibit the lowest levels of
TP53INP1 expression. Therefore, we examined mRNA expression
data from 122 human PDA tumors and controls,28,29 finding con-
sistent upregulation of Id3 in PDA relative to controls. Indeed, as
hypothesized, the analysis revealed a striking inverse correlation
between Id3 and TP53INP1 levels (P < 0.0001) (Fig. 2F), sug-
gesting loss of bHLH signaling as a novel mechanism for
TP53INP1 dysregulation in PDA.Induction of Acinar Cell Reprogramming by E47
Given the important role of bHLH proteins in acinar cell
development and homeostasis,35,36 we next examined whether
changes in transcriptional networks, via induced E47 activity,
could instruct PDA cells to regain a differentiated acinar cell state.
The first evidence that PDA cells could indeed revert to an acinar
identity was obtained through computational GSEA comparison
of our microarray data with a set of human pancreas-enriched
genes (GSE1133).30 As shown in Figure 3A, E47 significantly
induced an acinar gene signature profile, achieving an enrichment
score of 0.58 (P < 0.001), compared with a normalized enrich-
ment score of 1.8021667. Notably, similar results were obtained
using a second pancreatic gene set (P = 0.0014), normalized
enrichment score of 1.6041193 (Fig. S8A, Supplemental Digital
Content, http://links.lww.com/MPA/A363).31 Strikingly, E47
induced 28% of the most highly specific acinar genes (genes
enriched ≥ 50-fold in primary acinar tissue vs other primary
tissues) (Fig. 3B).722 www.pancreasjournal.comTo validate the GSEA results, we next measured transcript
levels of acinar gene products in PANC-1/E47, BxPC-3/E47,
and MiaPaCa2/E47 cells by qRT-PCR. Induction of E47 activity
rapidly generated dramatic (111 fold-253,016 fold) increases in
mRNA levels for digestive enzyme genes, including trypsin (tryp-
sin 2, trypsinogen, PRSS2), elastase 3 (ELA3), and carboxypep-
tidase A2 (CPA2), in all cell lines (Fig. 3C). Moreover, upon
removal of tamoxifen, enzyme expression was stable for at least
8 days (the longest period tested). Importantly, tamoxifen alone
did not induce enzyme gene expression in parental PDA cells
lacking inducible E47 (Fig. S8B, Supplemental Digital Con-
tent, http://links.lww.com/MPA/A363). Immunostaining of trypsin
(PRSS2) expression revealed that E47 also increased protein levels
(Fig. 3D) that continued to rise for a 7-day time course (Fig. S6,
Supplemental Digital Content, http://links.lww.com/MPA/A363).
Interestingly, although PRSS2, ELA3, and CPA2 are known tran-
scriptional targets of the bHLH protein PTF1a,37 Ptf1a mRNA ex-
pression was below the level of detection in PDA cells, and its
expression did not reach significant values in response to E47 in-
duction. Similar to Ptf1a, expression of Rbpjl, a member of the
PTF1 protein complex,38 and Hnf1a39 were low/absent in all 3 cell
lines ± tamoxifen, whereasNr5a240 andGata641 exhibited awider
expression range among cell lines but were also below normal
human exocrine tissue expression. In contrast, Rbpj38 was ex-
pressed in PDA/E47 lines at levels similar to normal exocrine
tissue levels but again its expression was not altered by E47. Sim-
ilarly, ductal gene transcripts for Sox9,Hnf1b, and Hnf6were also
relatively unchanged by E47 (Fig. S8C, Supplemental Digital
Content, http://links.lww.com/MPA/A363).© 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. E47 induces acinar cell differentiation in PDA cells. A, GSEA analysis of microarray data for E47-induced genes in PANC-1/E47 cells
(GSE55999) compared with human exocrine pancreas-enriched genes (GSE1133). The green curve is the running enrichment score
(P < 0.001). B, E47 induces seven of the 25 most highly specific exocrine pancreas genes identified in GSE1133; S1-S4,samples +E47 activity;
C1-C4, uninduced control samples. C, qRT-PCR for trypsinogen, carboxypeptidase A2 (CPA2), and elastase 3 (ELA3) in PDA/E47 cells with and
without E47-induced activity. D, Immunostaining for trypsinogen in PANC-1/E47 cells with induced E47 activity for 7 days, 400 (*P < 0.05,
**P < 0.01, ***P < 0.001, n = 3 per group). Results are representative of at least 3 independent experiments.
Pancreas • Volume 44, Number 5, July 2015 Reprogramming Pancreatic Cancer CellsWe next investigated whether the induction of acinar gene
products included activation of the acinar maturation pathways
normally regulated by the tissue-restricted bHLH protein MIST1.
Similar to PTF1a, downregulation ofMIST1 occurs during ADM.
Intriguingly, E47 activity rapidly led to significant induction of
Mist1 expression in all PDA/E47 lines (Figs. 4A, B, S6, Supple-
mental Digital Content, http://links.lww.com/MPA/A363). More-
over, ChIP analysis revealed that E47 directly targets the Mist1
promoter (Fig. 4C). MIST1 functions as an acinar scaling/
maturation factor, ensuring in part, proper cell-cell junctions,
and intracellular organization.23 To determine whether induced
MIST1 protein was functional in these cells, we first examined ex-
pression of the MIST1 target genes Foxp2, Copz2, and Rab3d.42
As predicted, expression of each MIST1 target was significantly
increased within 48-hour post-E47 activity (Fig. 4D). Moreover,
PDA/E47 cells also acquired MIST1-dependent acinar cell char-
acteristics, including the generation of ZO.1-containing tight junc-
tions and accumulation of an extensive intracellular actin network
(Fig. 4E).43 We previously showed that MIST1 is required for the
formation of Cx32-expressing gap junctions, a hallmark of differ-
entiated acinar tissue (Fig. S9A, Supplemental Digital Content,
http://links.lww.com/MPA/A363).6,7,14,23 Consistent with this ob-
servation, E47-induced PDA cells accumulated bothCx32mRNA
and gap junction complexes (Figs. 4F, G). To directly test whether
MIST1 expression was essential for E47-induced Cx32 expres-
sion, we next inhibited Mist1 expression by siRNA strategies.
As predicted, loss of MIST1 significantly reduced E47-induced
Cx32 expression (Fig. S9, Supplemental Digital Content,
http://links.lww.com/MPA/A363). Thus, E47 induces feed-forward© 2015 Wolters Kluwer Health, Inc. All rights reserved.activation of the bHLH gene Mist1, which is required for acinar
maturation in PDA cells.
Because we had previously shown that, similar to in-
creased E47 expression, Id3 knockdown reduced Ki67 expres-
sion in PDA cells,18 we considered that decreasing Id3 levels
might also induce acinar-specific gene expression. Indeed, in-
hibition of Id3 by siRNA significantly induced PRSS2 tran-
scripts (P = 0.003), recapitulating the observed results with
E47 upregulation (Fig. S10, Supplemental Digital Content,
http://links.lww.com/MPA/A363). These data support a model in
which E47 shifts the balance between functional bHLH/bHLH
complexes and nonfunctional bHLH/ID3 interactions, which
is also consistent with our studies showing direct interactions
between E47 and ID3 in PDA cells (Fig. S1B, Supplemental
Digital Content, http://links.lww.com/MPA/A363).E47 Inhibits PDA-Tumor Formation In Vivo
Because induced E47 activity was sufficient to convert PDA
cells to a stable quiescent and differentiated acinar cell state in
vitro, we hypothesized that altering the bHLH transcription net-
works might also reduce the tumor-forming potential of PDA cells
in vivo. Therefore, to begin to address the effects of E47 on tumor
growth dynamics, control PANC-1 cells and experimental PANC-
1/E47 cells were treated with tamoxifen in vitro for 8 days before
transplantation into immunocompromised mice. As shown in
Figure 5, during the course of 35 days, control parental PANC-1
cells treated with tamoxifen produced large tumors, whereas tu-
mors in mice transplanted with tamoxifen-induced PANC-1/E47www.pancreasjournal.com 723
FIGURE 4. E47 induces expression ofMist1 and MIST1 target genes in PDA cells. A, qRT-PCR for Mist1 transcripts in all PDA/E47 lines.
B, Immunostaining for MIST1 in PANC-1/E47 cells, 800. C, E47 ChIP assay on theMist1 promoter. E47 binding is enriched on theMist1
promoter in Panc1/E47 cells induced with tamoxifen. D, qRT-PCR for MIST1 target genes Foxp2, Copz2, and Rab3D. E, Immunostaining for
ZO.1, 800, and actin, 400. F, qRT-PCR for the gap junction protein connexin 32 (CX32) and quantification of the % CX32-expressing
cells in PANC-1/E47 cells. G, Immunostaining for CX32-containing gap junctions, 1200. White arrows in B, D, and F identify examples of
positive expression. *P < 0.05, **P < 0.01, ***P < 0.001, n = 3 per group.
FIGURE 5. E47 in vitro inhibits PDA cell tumorigenesis in vivo. PANC-1/E47 and parental PANC-1 cells were treated with tamoxifen for 8 days
in vitro before transplantation into SCID/beige mice. A, Tumor growth as measured by ultrasound. B, Comparison of animals and excised
tumors at 35 days posttransplant. Note that large tumors formed in tamoxifen-treated parental PANC-1 cells lacking ectopic E47, indicating
that E47, not tamoxifen, is responsible for reduced tumor growth. Representative of 3 independent experiments. C, Immunostaining for
trypsinogen (brown/orange cytoplasm), Ki67 (dark brown nuclei), and hemotoxylin nuclear counterstain in slides from explanted tumors.
Images are 100 and 400 original.
Kim et al Pancreas • Volume 44, Number 5, July 2015
724 www.pancreasjournal.com © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Pancreas • Volume 44, Number 5, July 2015 Reprogramming Pancreatic Cancer Cellscells were significantly reduced (~18-fold) relative to controls
(P = 0.00011) (Figs. 5A, B). To further examine the phenotype
of individual PANC-1 and PANC-1/E47 cells, tumors were ex-
planted after 35 days and processed for immunohistochemistry.
Remarkably, the small tumors arising from the PANC-1/E47 cells
treated with tamoxifen in vitro contained clusters of cells-
expressing trypsinogen (Fig. 5C). Moreover, these cells exhibited
reduced Ki67 expression relative to the control PANC-1 cell-
derived tumors. Thus, the acinar phenotype induced by E47 in
vitro remained stable in the absence of tamoxifen for at least
35 days in vivo. Because we have shown that growth arrested,
reprogrammed, PDA cells eventually die in vitro (Fig. S3, Supple-
mental Digital Content, http://links.lww.com/MPA/A363), the in
vivo findings are most consistent with a model in which a minor-
ity of cells, which do not contain the E47MER vector (Fig. S1,
Supplemental Digital Content, http://links.lww.com/MPA/A363)
form small tumors. Additional studies in the BxPC-3/E47 line re-
vealed that 2 days of tamoxifen treatment in vitro was sufficient to
significantly inhibit tumor formation in vivo (Fig. S11, Supple-
mental Digital Content, http://links.lww.com/MPA/A363). Thus,
the data establish that E47 reprogramming of PDA cells in vitro
reduces tumorigenesis in vivo.
Collectively, our data establish for the first time that E47 repro-
grams aggressive PDA cells to a quiescent acinar state by restoring
expression of p21, TP53INP1, acinar enzymes, andMIST1 (Fig. 6).
Importantly, reprogramming greatly diminishes the tumor pro-
moting potential of PDA cells, a finding with broad implications
for therapeutic advancement for this highly lethal disease.FIGURE 6. Proposed model of mechanisms underlying E47/ID3
regulation of growth, acinar differentiation, and tumorigenicity in
human PDA.Our workingmodel is that high levels of ID3 contribute
to tumorigenicity by inhibiting the bHLH transcriptional network.
Conversely, E47 induces G0/G1 arrest via p21 and TP53INP1
induction and downregulation of cell cycle activators (eg, aurora
kinase, topoisomerase, cyclinb2). Concurrently, E47 induces an acinar
differentiation program that is characterized by re-expression of
digestive enzymes, upregulation ofMist1, and its target genes and
re-establishment of cell-cell junctions. Together, the combined
activities of E47 constrain tumor growth.
© 2015 Wolters Kluwer Health, Inc. All rights reserved.DISCUSSION
Given the multitude of genome-wide alterations in PDA and
the fact that many of the commonly studied human PDA cell lines
have been cultured in laboratories for more than 30 years,44 it
seemed doubtful that highly tumorigenic cells could retain the
capacity to revert to a quiescent, differentiated acinar cell state.
Yet, because we had previously uncovered powerful roles for
bHLH and HLH transcription factors in the pancreas,7,12,14,32
we hypothesized that dysregulated bHLH/HLH activity could be
integral to PDA pathogenesis. Although E47 expression is not
downregulated in PDA relative to control tissue, an inhibitor
E47 activity, ID3, becomes highly expressed in PDA, suggesting
loss of E47 function in PDA. The first evidence that this was true
was our finding that either downregulation of ID3 or induced
expression of E47 lowered Ki67 expression in the PANC-1 cell
line.18 Here, we report the extraordinary finding that E47 induces
G0/G1 arrest, promotes a high degree of acinar differentiation, and
profoundly reduces the tumor-promoting potential of PDA cells.
All PDA cell lines tested responded to E47 with upregulation
of p21 and TP53INP1 gene expression associated with G0/G1
arrest. It has been shown that p21 and TP53INP1 are each down-
regulated in PDA and that their re-expression in PDA cells results
in growth arrest.33,34 To our knowledge, however, this is the first
demonstration that a common mechanism (bHLH activity) coor-
dinately controls both genes. Further, we show that the action of
E47 on the p21 promoter is direct, consistent with several reports
showing that E47 and other bHLH factors bind to and regulate the
p21 promoter.34,45–47
An additional link between the bHLH/ID axis and TP53INP1
expression was revealed by our finding of a significant inverse
relationship between Id3 and TP53INP1 expression in RNA from
human PDA tumors. Thus, PDA tumors with the highest ex-
pression of Id3 mRNA harbored the lowest level of TP53INP1
transcripts. Together, our data suggest a novel regulatory network
in PDAwhereby elevated ID3 may be responsible for the loss of
both p21 and TP53INP1 gene expression through inhibition of
bHLH factor activity.
Remarkably, we find that concurrent with growth arrest, E47
expression promotes acinar differentiation of PDA cells. All of
the PDA cell lines tested exhibited robust induction of digestive
enzyme gene expression. Interestingly, although digestive enzyme
genes are known targets of the acinar-restricted bHLH factor
PTF1a,17,20,37 Ptf1a expression was generally below the limit of
detection in PDA/E47 induced for 2 to 3 days as in parental
PDA cells. Consistent with the latter, Dufresne et al20 also
reported low/absent PTF1a expression in human and murine
PDA tissue. Therefore, our data are most consistent with a model
in which E47 is capable of substituting for PTF1a to induce the
level of enzyme observed here. The E47-induced shift towards
acinar differentiation is not complete, however, as the level of
most acinar genes tested remains below normal tissue levels.
Therefore, given the important role of Ptf1a in the exocrine pan-
creas, PTF1a may be required to promote enzyme expression to
the levels expressed by primary cells and/or to induce the full
complement of acinar genes. We also found that expression of
Rbpjl, which is required for PTF1a function in mature cells, is
below the limits of detection in the 3 PDA/E47 cell lines.
The MIST1 bHLH factor and its downstream transcription
network, which are responsible for acinar cell maturation and
formation of acinar cell junctions, were clearly elevated by E47
activity, indicating that E47 amplifies bHLH signaling in a feed-
forward fashion. Our findings are consistent with reports demon-
strating that Mist1 is influential in converting embryonic stem
cells to an acinar cell fate.48 The data also support our previouswww.pancreasjournal.com 725
Kim et al Pancreas • Volume 44, Number 5, July 2015in vivo studies showing that loss of MIST1 activity dramatically
enhances ADM/PanIN formation in KrasG12D-expressing acinar
cells, whereas sustainedMist1 expression produces a greatly atten-
uated KrasG12D-induced transformation response.7,8 Interestingly,
we find that E47 binds directly to the MIST1 promoter as it does
to the p21 promoter, suggesting that bHLH signaling may be the
final common denominator between growth and differentiation.
Future studies will address whether E47 binds to the p21 and
Mist1 promoters as homodimers or as heterodimers with other
bHLH partners (eg, E12, HEB, MIST1) and whether E47 is
unique in its ability to reprogram PDA cells. In contrast to acinar
genes, the ductal genes we analyzed were not highly influenced by
E47, although a more exhaustive survey of ductal gene expression
will be needed to precisely define the degree to which E47 in-
duced PDA cells to transition back towards a more normal acinar
cell state.
The data are consistent with a mechanism inwhich E47 over-
expression acts in part as a sponge for the high levels of ID3
observed in PDA cells. We show that E47 complexes with ID3
in PDA cells and that ID3 knockdown, like E47 upregulation, in-
duces growth arrest18 and trypsinogen expression. Thus, targeting
ID3 to shift the bHLH/ID balance may also be a promising
approach to treating PDA. Indeed, strategies based on inhibition
of other ID family members are currently in clinical trials for
ovarian cancer and glioma.49,50
To our knowledge, this is the first report showing that ectopic
expression of a single gene (E47) is sufficient to cause G0/G1
quiescence, acinar differentiation, and activation of the MIST1
network in PDA cells. Further, the stable nature of E47-induced
reprogramming to quiescent cells with acinar characteristics in
vitro was striking. These findings prompted us to ask whether
the growth arrest and acinar gene expression induced in vitro
might be sufficient to diminish the tumor-forming potential of
these aggressively growing cells. Indeed, temporary induction of
E47 for 2 to 8 days in vitro produced stable cell cycle arrest and
trypsinogen expression in transplanted human PDA cells. It will
now be of interest to investigate the effects of E47 on the growth
dynamics of established tumors.
Our observation that PDA cells retain the plasticity to be
forced back towards an acinar-like differentiated state despite their
many genomic alterations is consistent with recent studies1,2
showing that inactivation of KrasG12D expression in established
acinar-derived PanINs is sufficient to revert transformed cells
back to their previous differentiated acinar phenotype. Thus,
perturbation of at least 2 pathways, Kras signaling2 or shifting
the bHLH/HLH axis, can have a dramatic effect on PDA cell
growth and differentiation status. These multiple lines of evidence
establish that PDA cells clearly retain memory of their acinar
cell lineage. How the bHLH transcription network inhibits the
oncogenic activity of KrasG12D to promote acinar differentiation
properties remains as yet unknown. Importantly, however, we
have generated a rich microarray dataset (GSE55999), which is
generating testable hypotheses regarding the intersections between
E47 and oncogenic signaling pathways in PDA.
Presently, PDA is treated with cytotoxic agents, yet the aver-
age survival for PDA patients postdiagnosis is merely 6 months,
and improvements in therapies aremeasured in days.51 Thus, there
is an urgent need to devise novel strategies to combat this disease.
We conclude that the bHLH/ID axis acts as a pivotal hub through
which oncogenes and tumor suppressors exert control over acinar
cellular homeostasis. These studies have employed immortalized
human pancreatic cancer cell lines to provide a proof of concept
and to investigate mechanisms of action. In future studies, it will
be important to investigate the role of E47 in primary patient-
derived tumor tissue to determine whether targeting the bHLH/ID726 www.pancreasjournal.comaxis can provide a novel therapeutic approach to combating this
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